India recommends anti-dumping duty on Chinese chemical used in dye industry
India's Directorate General of Trade Remedies (DGTR) has recommended imposition of anti-dumping duty on a Chinese chemical used in the pharmaceutical industry, following an investigation that found the chemical was being exported to India at below-fair-market prices, injuring domestic producers.
The investigation involved a pharmaceutical intermediate (a chemical used in the synthesis of active pharmaceutical ingredients or APIs), where India's domestic manufacturer alleged that Chinese exporters were undercutting prices and suppressing domestic profitability.
Preliminary findings confirmed a dumping margin above the minimum threshold, indicating significant price undercutting by Chinese suppliers relative to the normal value in China.
The DGTR recommendation goes to the Ministry of Finance, which takes the final decision on whether to impose the duty — the government has final discretion and has in some previous cases declined to impose recommended duties (to protect downstream pharmaceutical users from higher input costs).
This recommendation is part of a broader pattern: India has imposed or initiated anti-dumping investigations on multiple Chinese chemicals in recent years, reflecting both trade remedy needs and the strategic objective of reducing pharmaceutical import dependence on China.
Anti-Dumping Duties: Mechanism and India's Framework
Dumping occurs when a country's exporters sell goods in a foreign market at prices below their "normal value" — typically the price in the exporting country's domestic market or the cost of production. Anti-dumping duties (ADD) are a trade remedy permitted under WTO's Anti-Dumping Agreement (ADA), which allows importing countries to impose additional tariffs to offset the dumping margin. In India, the process involves three agencies: the DGTR (investigation and recommendation), the Ministry of Finance (final imposition order), and the Ministry of Commerce (policy oversight).
Key Details
- DGTR (Directorate General of Trade Remedies): statutory body under MoC; investigates anti-dumping, countervailing duty, and safeguard cases
- Normal value: comparable price of the product in the exporting country's domestic market; if export price < normal value, dumping is said to occur
- Dumping margin: (Normal value – Export price) / Normal value; must be above de minimis (2%) to warrant duty
- Material injury test: DGTR must also prove that dumping caused material injury (or threat thereof) to domestic industry
- Anti-dumping duty duration: typically 5 years, subject to sunset review
- WTO ADA (Anti-Dumping Agreement): Article VI of GATT 1994; allows ADD as an exception to MFN treatment
The DGTR's recommendation followed the standard investigation process, establishing both dumping and material injury to Indian producers — a two-pronged test that must be satisfied under WTO rules before a duty can be legally imposed.
India's Pharmaceutical Sector and API Import Dependence on China
India is the world's largest provider of generic medicines by volume — the "pharmacy of the world" — supplying over 20% of global generics by volume. However, this manufacturing strength is built on a significant vulnerability: heavy dependence on China for Active Pharmaceutical Ingredients (APIs) and key starting materials (KSMs). Approximately 68% of India's bulk drug imports by value come from China. During the COVID-19 pandemic, this dependence became a national security concern, prompting the PLI (Production-Linked Incentive) scheme for bulk drugs.
Key Details
- India's share of global generic medicines: ~20% by volume; over 50% of generic supply to the US
- API import dependence on China: ~68% of India's bulk drug API imports (by value) from China
- PLI Scheme for Bulk Drugs (2020): ₹6,940 crore incentive to promote domestic API manufacturing, covering 41 critical APIs
- Pharma Clusters: dedicated bulk drug parks approved in Gujarat, Andhra Pradesh, Himachal Pradesh
- Critical API vulnerability: paracetamol, penicillin, vitamins, fermentation-based APIs — predominantly China-sourced
- Anti-dumping dilemma: imposing duty raises input costs for Indian pharma manufacturers; not imposing lets domestic API producers face unfair Chinese competition
The DGTR recommendation highlights the structural tension in India's pharma sector: protecting domestic chemical/API producers through anti-dumping duties raises input costs for the much larger downstream formulation industry — which is why the Finance Ministry sometimes overrides DGTR recommendations for pharma chemicals.
India-China Trade Remedies: A Pattern of Escalation
Since 2016, India has significantly ramped up its use of anti-dumping, countervailing, and safeguard measures against Chinese imports — across chemicals, steel, electronics, and textiles. China is the single largest target of India's trade remedy actions globally. This reflects both a genuine market distortion concern (China's state subsidies enable below-cost exports) and a strategic objective of reducing China-dependence in sensitive sectors. The ongoing Indo-China border tensions since 2020 (Galwan Valley) have added a geopolitical dimension to what are formally economic trade remedy decisions.
Key Details
- India is among the top users of anti-dumping measures globally; China is India's top target country
- Post-Galwan 2020: India imposed FDI restrictions on Chinese companies, banned 300+ Chinese apps, tightened custom checks on Chinese goods
- Pharmaceutical chemicals from China subject to multiple ADD investigations: Vitamin A Palmitate, Ceftriaxone Sodium, acetonitrile, dicyandiamide, DASDA, and now the current pharma intermediate
- India's self-reliance (Atmanirbhar Bharat) framework explicitly targets pharmaceutical API dependence reduction
- WTO dispute risk: China has challenged some Indian ADD measures at WTO; India defends on injury grounds
The latest DGTR recommendation is one more step in India's deliberate strategy to use trade remedy law — within WTO-permissible bounds — to create space for domestic API manufacturers to compete against heavily subsidised Chinese exporters.
- DGTR (Directorate General of Trade Remedies): recommends anti-dumping duties; under Ministry of Commerce
- Chemical subject: pharmaceutical intermediate (chemical input used in API or drug synthesis); details subject to official notification
- Finding: dumping margin above de minimis threshold; material injury to domestic Indian producer established
- Final decision: Ministry of Finance — can accept or reject DGTR recommendation
- India's API import dependence on China: ~68% of bulk drug imports by value
- PLI Scheme for Bulk Drugs (2020): ₹6,940 crore; covers 41 critical APIs to reduce China dependence
- Anti-dumping duty duration if imposed: 5 years (subject to sunset review)
- WTO ADA: authorises anti-dumping duties where dumping + material injury are both proven
- India has imposed or initiated ADD on multiple Chinese chemicals: Vitamin A Palmitate, Ceftriaxone Sodium, acetonitrile, hexamine, ethyl chloroformate, DASDA, and others